EC
Endurant Capital Management LP
13F filer · CIK 0001633055Last filed May 7, 2024
Inactive · not filing 13F
13F portfolio value$0U.S. long equity reported on 13F
Positions00 new · 24 closed
Net flow last quarter-$17.8MBuys minus sells
Top 10 positions weightNot reportedConcentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q1 2024Reported May 7, 20240 positions | |||||
| Q4 2023Reported Feb 14, 202424 positions | |||||
| $2.26M | 12.96% | 0.00% | -18.3% | Q4 2014 | |
| $2.01M | 11.55% | 0.00% | -72.6% | Q4 2014 | |
| AAXNXAxonics, Inc. | $1.55M | 8.87% | 0.05% | Not reported | Q3 2019 |
| $1.24M | 7.10% | 0.00% | -80.5% | Q4 2014 | |
| $1.04M | 5.94% | 0.00% | Not reported | Q1 2018 | |
| $859K | 4.92% | 0.01% | Not reported | Q4 2018 | |
| $848K | 4.86% | 0.01% | -56.0% | Q1 2015 | |
| HHOLXHologic Inc | $831K | 4.76% | 0.00% | -34.5% | Q4 2014 |
| $687K | 3.94% | 0.00% | -67.7% | Q4 2014 | |
| $562K | 3.22% | 0.00% | -89.2% | Q1 2020 | |
| $552K | 3.16% | 0.01% | -73.1% | Q1 2019 | |
| $455K | 2.61% | 0.00% | Not reported | Q4 2014 | |
| $448K | 2.57% | 0.00% | -97.4% | Q1 2017 | |
| $437K | 2.50% | 0.06% | -80.9% | Q3 2020 | |
| $414K | 2.38% | 0.00% | -77.3% | Q4 2014 | |
| $379K | 2.17% | 0.01% | -80.8% | Q4 2014 | |
| $374K | 2.14% | 0.00% | -91.4% | Q2 2018 | |
| $286K | 1.64% | 0.01% | -90.2% | Q3 2017 | |
| $264K | 1.51% | 0.00% | Not reported | Q4 2014 | |
| $244K | 1.40% | 0.01% | New | Q4 2023 | |
| $227K | 1.30% | 0.00% | Not reported | Q2 2015 | |
| $215K | 1.23% | 0.00% | -92.9% | Q4 2014 | |
| $203K | 1.17% | 0.00% | -91.5% | Q4 2014 | |
| $156K | 0.89% | 0.21% | Not reported | Q1 2019 | |
| Q3 2023Reported Nov 14, 202341 positions | |||||
| $15.9M | 14.27% | 0.10% | +311.8% | Q1 2017 | |
| $7.01M | 6.30% | 0.00% | Not reported | Q4 2014 | |
| $6.93M | 6.23% | 0.08% | +629.9% | Q1 2015 | |
| $6.53M | 5.87% | Not reported | +58.6% | Q2 2019 | |
| $5.88M | 5.28% | 0.01% | +139.6% | Q4 2014 | |
| $4.78M | 4.30% | 0.03% | Not reported | Q1 2020 | |
| $4.57M | 4.10% | 0.00% | -10.0% | Q4 2014 | |
| $4.48M | 4.02% | 0.02% | +255.1% | Q1 2022 | |
| $4.23M | 3.80% | 0.14% | Not reported | Q1 2016 | |
| $3.67M | 3.29% | 0.02% | Not reported | Q2 2018 | |
| $3.2M | 2.88% | 0.01% | Not reported | Q4 2014 | |
| $2.93M | 2.63% | 0.06% | Not reported | Q1 2022 | |
| $2.84M | 2.55% | 0.09% | Not reported | Q3 2017 | |
| $2.66M | 2.38% | 0.03% | Not reported | Q3 2022 | |
| $2.53M | 2.27% | 0.00% | -21.5% | Q4 2014 | |
| $2.25M | 2.02% | 0.30% | +555.1% | Q3 2020 | |
| $2.09M | 1.88% | 0.01% | Not reported | Q4 2014 | |
| $2.06M | 1.85% | 0.00% | Not reported | Q4 2014 | |
| $2.01M | 1.80% | 0.06% | Not reported | Q3 2017 | |
| $1.96M | 1.76% | 0.01% | Not reported | Q4 2014 | |
| $1.95M | 1.75% | 0.04% | Not reported | Q4 2014 | |
| $1.93M | 1.73% | 0.01% | Not reported | Q2 2022 | |
| $1.79M | 1.61% | 0.03% | -53.2% | Q1 2019 | |
| $1.75M | 1.57% | 0.00% | Not reported | Q4 2014 | |
| $1.74M | 1.56% | 0.00% | -76.4% | Q4 2014 | |
| $1.42M | 1.27% | 0.01% | Not reported | Q1 2015 | |
| 8ETNB89bio, Inc. | $1.27M | 1.14% | 0.11% | +180.6% | Q4 2022 |
| HHOLXHologic Inc | $1.23M | 1.11% | 0.01% | Not reported | Q4 2014 |
| $1.11M | 1.00% | 0.45% | -4.0% | Q1 2018 | |
| $975K | 0.88% | 0.03% | New | Q3 2023 | |
| $847K | 0.76% | 0.14% | Not reported | Q1 2021 | |
| $818K | 0.74% | 0.07% | Not reported | Q4 2019 | |
| $787K | 0.71% | 0.02% | Not reported | Q3 2018 | |
| $776K | 0.70% | 0.00% | -79.4% | Q2 2018 | |
| $723K | 0.65% | 0.11% | +45.8% | Q2 2023 | |
| VBVTYXVentyx Biosciences, Inc. | $641K | 0.58% | 0.03% | New | Q3 2023 |
| AACLXArcellx, Inc. | $508K | 0.46% | 0.03% | New | Q3 2023 |
| $491K | 0.44% | Not reported | Not reported | Q4 2020 | |
| $481K | 0.43% | 0.29% | -33.9% | Q4 2019 | |
| $301K | 0.27% | 0.01% | New | Q3 2023 | |
| ATADAPYAdaptimmune Therapeutics PLC | $243K | 0.22% | 0.02% | -62.0% | Q1 2020 |
| Q2 2023Reported Aug 14, 202328 positions | |||||
| $7.24M | 6.32% | 0.01% | -7.1% | Q4 2014 | |
| $5.69M | 4.97% | 0.00% | -0.5% | Q4 2014 | |
| $5.5M | 4.80% | 0.02% | Not reported | Q4 2014 | |
| $4.72M | 4.12% | 0.06% | -3.1% | Q1 2019 | |
| $4.35M | 3.80% | Not reported | -37.5% | Q2 2019 | |
| $4.31M | 3.76% | 0.01% | Not reported | Q2 2018 | |
| $3.78M | 3.30% | 0.02% | -82.9% | Q1 2017 | |
| $3.53M | 3.08% | 0.00% | -82.6% | Q4 2014 | |
| $3.3M | 2.88% | 0.00% | Not reported | Q4 2014 | |
| $3M | 2.62% | 0.01% | Not reported | Q4 2014 | |
| $2.82M | 2.47% | 0.03% | -65.0% | Q2 2015 | |
| $2.5M | 2.19% | 0.00% | -84.9% | Q4 2014 | |
| $2.39M | 2.09% | 0.00% | Not reported | Q4 2014 | |
| $2.21M | 1.93% | 0.03% | +23.6% | Q4 2018 | |
| $1.97M | 1.72% | 0.01% | Not reported | Q3 2022 | |
| $1.9M | 1.66% | 0.47% | -28.1% | Q1 2018 | |
| $1.68M | 1.46% | 0.06% | -65.5% | Q3 2017 | |
| $1.32M | 1.15% | 0.00% | -9.2% | Q1 2017 | |
| $1.13M | 0.98% | 0.01% | Not reported | Q1 2015 | |
| $1M | 0.87% | 0.00% | -58.2% | Q1 2022 | |
| $768K | 0.67% | 0.45% | -68.3% | Q4 2019 | |
| ATADAPYAdaptimmune Therapeutics PLC | $759K | 0.66% | 0.06% | -50.6% | Q1 2020 |
| $729K | 0.64% | 0.01% | Not reported | Q4 2016 | |
| 8ETNB89bio, Inc. | $555K | 0.48% | 0.04% | +49.5% | Q4 2022 |
| $471K | 0.41% | 0.05% | Not reported | Q3 2020 | |
| MMASIMasimo Corp | $469K | 0.41% | 0.01% | Not reported | Q1 2018 |
| $363K | 0.32% | 0.10% | New | Q2 2023 | |
| $336K | 0.29% | 0.02% | -63.6% | Q1 2018 | |
Premium opens every quarter this fund has filed